Ocakoglu, KasimEr, OzgeErsoz, Onur AlpLambrecht, Fatma YurtInce, MineKayabasi, CaglaGunduz, Cumhur2019-10-272019-10-2720161773-22471773-2247https://doi.org/10.1016/j.jddst.2016.04.005https://hdl.handle.net/11454/52736Photodynamic therapy (PDT) is a medical treatment for the removal of target tissues involving the delivery of a photosensitizer agent followed by irradiation with visible light. In the present study, symmetric Zn(II)Pc 1 and asymmetrically substituted Zn(II)Pc 2 were synthesized and examined multifunctional agents for tumor nuclear imaging, and PDT potential. The Zn(II)Pc 1 and Zn(II)Pc 2 were radiolabeled with I-131 with high efficiency (93.4 +/- 1.6% and 91.4 +/- 1.6%, respectively). The results of the biodistribution study showed that radiolabeled Zn(II)Pc 1 had high uptake on lung, large intestine, ovary and pancreas. However, the uptake of radiolabeled Zn(II)Pc 2 was statically significant in pancreas and intestine. In PDT studies, EMT6/P (mouse mammary cell) and HeLa (cervical adenocarcinoma cell) with Zn(II)Pc 1 and Zn(II)Pc 2 were exposed to red light at the doses of 10-30 J/cm(2). Although PDT activity of Zn(II)Pc 2 in HeLa cell line was determined, Zn(II)Pc 1 showed no phototoxic effect in both cell lines. In conclusion, radiolabeled Zn(II)Pc 1 might be a promising imaging agent for the lung, the ovary pancreas, and the colon tumors. However, radiolabeled Zn(II)Pc 2 might be a promising nuclear imaging agent for the colon and the pancreas tumors and promising PDT agent for cervical tumors. (C) 2016 Elsevier B.V. All rights reserved.en10.1016/j.jddst.2016.04.005info:eu-repo/semantics/closedAccessPhotodynamic therapyCancerBiodistributionI-131RadiolabelingPhthalocyanineArticle33164169WOS:000378453600018Q1Q4